Show simple item record

dc.contributor.authorRaijmakers, NJH
dc.contributor.authorZijlstra, M
dc.contributor.authorvan Roij, J
dc.contributor.authorHusson, O
dc.contributor.authorOerlemans, S
dc.contributor.authorvan de Poll-Franse, LV
dc.date.accessioned2019-01-08T10:25:11Z
dc.date.issued2018-10-01
dc.identifier.citationSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, 26 (10), pp. 3397 - 3404
dc.identifier.issn0941-4355
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2996
dc.identifier.eissn1433-7339
dc.identifier.doi10.1007/s00520-018-4181-6
dc.description.abstractPURPOSE: The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS: Between 2008 and 2015, cancer patients were invited to participate in PROFILES (Patient Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship) registry studies. Patients were eligible for inclusion in this secondary analysis if they had been invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in their last year of life (N = 892). Four hundred fifty-eight patients (51%) responded. Descriptive statistics were used to describe the HRQoL of cancer patients in the last 3 months of life (N = 61), the last 3-6 months (N = 110), the last 6-9 months (N = 138), or the last 9-12 months of their life (N = 129). RESULTS: Patients in the last 3 months report a significant lower HRQoL, lower functioning, and higher symptom burden of fatigue and appetite loss compared to patients in different time periods before death (p < 0.008). Clinical relevance of the differences for global QoL, cognitive, and social functioning was large. Patients' HRQoL in the last year of life was significantly lower than that of the normative population (p < 0.001). CONCLUSIONS: All aspects of HRQoL are considerably impaired in patients with advanced cancer, with a marked lower HRQoL in the final months of life. This marked decline of HRQoL in the final months of life may be an indicator of approaching death and serve as an important trigger for end-of-life communication and decision-making about subsequent treatment and supportive care.
dc.formatPrint-Electronic
dc.format.extent3397 - 3404
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGER
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectTerminal Care
dc.subjectQuality of Life
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectSurveys and Questionnaires
dc.titleHealth-related quality of life among cancer patients in their last year of life: results from the PROFILES registry.
dc.typeJournal Article
dcterms.dateAccepted2018-03-23
rioxxterms.versionofrecord10.1007/s00520-018-4181-6
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublished
pubs.volume26
pubs.embargo.termsNot known
icr.researchteamClinical and Translational Sarcoma
dc.contributor.icrauthorHusson, Olga


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record